MarketAxess (NASDAQ:MKTX) and Dominari (NASDAQ:DOMH) Head-To-Head Comparison

MarketAxess (NASDAQ:MKTX) and Dominari (NASDAQ:DOMH) are both finance companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Insider & Institutional Ownership

99.0% of MarketAxess shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 2.7% of MarketAxess shares are held by insiders. Comparatively, 9.7% of Dominari shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares MarketAxess and Dominari’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MarketAxess	33.83%	20.82%	14.17%
Dominari	-721.11%	-38.40%	-35.22%

Volatility & Risk

MarketAxess has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for MarketAxess and Dominari, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MarketAxess	2	6	3	0	2.09
Dominari	0	0	0	0	N/A

MarketAxess presently has a consensus price target of $249.73, indicating a potential upside of 24.53%. Given MarketAxess’ higher probable upside, equities research analysts plainly believe MarketAxess is more favorable than Dominari.

Earnings & Valuation

This table compares MarketAxess and Dominari’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MarketAxess	$752.55 million	10.10	$258.05 million	$6.81	29.45
Dominari	$2.04 million	5.44	-$22.88 million	($4.64)	-0.40

MarketAxess has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than MarketAxess, indicating that it is currently the more affordable of the two stocks.

Summary

MarketAxess beats Dominari on 11 of the 12 factors compared between the two stocks.

About MarketAxess

MarketAxess Holdings Inc., together with its subsidiaries, operates an electronic trading platform for institutional investor and broker-dealer companies worldwide. The company offers trading technology that provides liquidity access in U.S. high-grade bonds, U.S. high-yield bonds, emerging market debt, eurobonds, municipal bonds, U.S. government bonds, and other fixed-income securities; and executes bond trades between and among institutional investor and broker-dealer clients in an all-to-all anonymous trading environment for corporate bonds through its Open Trading protocols. It also provides trading-related products and services, including composite+ pricing and other market data products to assist clients with trading decisions; auto-execution and other execution services for clients requiring specialized workflow solutions; connectivity solutions that facilitate straight-through processing; and technology services to optimize trading environments. In addition, the company offers various pre-and post-trade services, such as trade matching, trade publication, regulatory transaction reporting, and market and reference data across a range of fixed-income and other products. MarketAxess Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.